Results 111 to 120 of about 20,100 (304)
Xenotransplantation, Volume 32, Issue 4, July/August 2025.ABSTRACT Xenotransplantation is becoming an emerging field of interest for the treatment of end‐stage heart disease. In fact, the shortage of human heart donors in European countries requires the increasing investigation of alternative strategies such as heart xenotransplantation.
Nicola Pradegan +6 more
wiley +1 more source
Blood, 2019 Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement-inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH).
A. Kulasekararaj +18 more
semanticscholar +1 more source
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
Annals of Clinical and Translational Neurology, Volume 12, Issue 6, Page 1162-1170, June 2025.ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib +16 more
wiley +1 more source
Application of a policy framework for the public funding of drugs for rare diseases [PDF]
, 2014 BACKGROUND: In many countries, decisions about the public funding of drugs are preferentially based on the results of randomized trials. For truly rare diseases, such trials are not typically available, and approaches by public payers are highly variable.
Christine Seager +10 more
core +1 more source
Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. [PDF]
, 2014 The alternative pathway of complement is implicated in the pathogenesis of several renal diseases, such as atypical hemolytic uremic syndrome, dense deposit disease and other forms of C3 glomerulopathy.
Józsi, Mihály +6 more
core +1 more source
Clinical Case Reports, Volume 13, Issue 6, June 2025.ABSTRACT Hypertensive emergency is an acute, significant elevation of blood pressure accompanied by end‐organ damage. We present a case of a 27‐year‐old gentleman who acquired multiple complications of hypertensive emergency, including renal failure and microangiopathy.
Tatiana Gusan +4 more
wiley +1 more source
Remission of aHUS neurological damage with eculizumab [PDF]
Clinical Kidney Journal, 2015 Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic ...
Maria Perez-Ebri +5 more
openaire +3 more sources
Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations [PDF]
, 2013 Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are ...
Alberti, M. +8 more
core +1 more source
PLoS ONE, 2020 BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert +19 more
doaj +1 more source
Complement inhibitors for age-related macular degeneration [PDF]
, 2014 Given the relatively high prevalence of age-related macular degeneration (AMD) and the increased incidence of AMD as populations age, the results of trials of novel treatments are awaited with much anticipation.
Chakravarthy, Usha +2 more
core +1 more source